Hovione and IDC Intranasal Drug Delivery Platform Available for Commercial Partnerships
Its lead single-use nasal dry powder device now available for commercial partnerships
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Its lead single-use nasal dry powder device now available for commercial partnerships
Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Irish Examiner, 21 june 2021
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®
Hovione is Growing
Executiva, 23 February 2026